Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
247.69
+7.92 (3.30%)
At close: Sep 16, 2026, 4:00 PM EDT
242.74
-4.95 (-2.00%)
After-hours: Sep 16, 2026, 7:57 PM EDT
Ascendis Pharma Employees
Ascendis Pharma had 1,189 employees as of December 31, 2025. The number of employees increased by 172 or 16.91% compared to the previous year.
Employees
1,189
Change (1Y)
172
Growth (1Y)
16.91%
Revenue / Employee
$1,006,042
Profits / Employee
$712,727
Market Cap
16.27B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,189 | 172 | 16.91% |
| Dec 31, 2024 | 1,017 | 138 | 15.70% |
| Dec 31, 2023 | 879 | 82 | 10.29% |
| Dec 31, 2022 | 797 | 158 | 24.73% |
| Dec 31, 2021 | 639 | 157 | 32.57% |
| Dec 31, 2020 | 482 | 152 | 46.06% |
| Dec 31, 2019 | 330 | 114 | 52.78% |
| Dec 31, 2018 | 216 | 79 | 57.66% |
| Dec 31, 2017 | 137 | 36 | 35.64% |
| Dec 31, 2016 | 101 | 23 | 29.49% |
| Dec 31, 2015 | 78 | 23 | 41.82% |
| Dec 31, 2014 | 55 | 10 | 22.22% |
| Dec 31, 2013 | 45 | 7 | 18.42% |
| Dec 31, 2012 | 38 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioNTech SE | 7,807 |
| BioMarin Pharmaceutical | 3,221 |
| Genmab | 3,119 |
| Jazz Pharmaceuticals | 2,890 |
| Incyte | 2,844 |
| Exelixis | 1,077 |
| BridgeBio Pharma | 1,003 |
| Madrigal Pharmaceuticals | 915 |
ASND News
- 1 day ago - Ascendis Pharma falls -12.8% - TheFly
- 1 day ago - Ascendis Pharma falls -12.1% - TheFly
- 1 day ago - Ascendis Pharma Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 1 day ago - Ascendis Pharma downgraded to Outperform from Strong Buy at Raymond James - TheFly
- 2 days ago - Ascendis Pharma to regain rights to TransCon technology-based products - TheFly
- 2 days ago - Ascendis Pharma announces $400M share repurchase plan - TheFly
- 2 days ago - Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases - GlobeNewsWire
- 2 days ago - Ascendis Announces Planned $400 Million Share Repurchase Program - GlobeNewsWire